

INFORMATION DISCLOSURE STATEMENT BY APPLICANT SHEET 1 OF 4	ATTY. DOCKET NO. 302.1	APPLICATION NO. 10/814,503
	APPLICANT Henry Lardy, et al	
	FILING DATE 30-Mar-2004	GROUP 1617

U.S. PATENTS						
EXAMINER INITIAL	PATENT OR PUBLICATION NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING / PRIORITY DATE
	3,332,967	07-25-67	Oliveto, et al			
	4,457,925	07-03-84	Bittler, et al			
	4,898,694	02-06-90	Schwartz et al			
	5,028,631	07-02-91	Schwartz et al			
	5,292,730	03-08-94	Lardy			
	5,296,481	03-22-94	Partidge, et al			
	5,332,582	07-26-94	Babcock, et al			
	5,372,996	12-13-94	Labrie			
	5,387,583	02-07-95	Loria			
	5,424,463	06-13-95	Lardy, et al			
	5,506,223	04-09-96	Lardy, et al			
	5,532,230	07-02-96	Daynes, et al			
	5,567,830	10-22-96	Upasani			
	5,641,766	06-24-97	Lardy			
	5,646,136	07-08-97	Petrow, et al			
	5,686,438	11-11-97	Daynes, et al			
	5,732,455	03-03-98	Tanabe, et al			
	5,744,462	04-28-98	Schwartz et al			06-07-95
	5,763,433	06-09-98	Morfin			06-21-95
	5,859,900	01-12-99	Dowell, et al			11-07-97
	5,912,240	06-15-99	Loria			04-10-97
	5,922,701	07-13-99	Araneo			07-28-97
	5,925,630	07-20-99	Upasani, et al			06-06-96
	5,939,545	08-17-99	Upasani, et al			07-02-97
	5,977,095	11-02-99	Araneo, et al			06-05-97
	6,046,185	04-04-00	Burgoyne, et al			07-10-97
	6,110,906	08-29-01	Labrie			07-21-94

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT SHEET 2 OF 4	ATTY. DOCKET NO. 302.1	APPLICATION NO. 10/814,503
	APPLICANT Henry Lardy, et al	
	FILING DATE 30-Mar-2004	GROUP 1617

U.S. PATENTS						
EXAMINER INITIAL	PATENT OR PUBLICATION NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING / PRIORITY DATE
	6,277,838	08-21-01	Upasani, et al			11-11-00
	6,667,299	12-23-03	Ahlem et al			03-23-00
	6,790,842	09-14-04	Bohlmann et al			06-26-00

U.S. PATENT APPLICATIONS						
EXAMINER INITIAL	PATENT OR PUBLICATION NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING / PRIORITY DATE
	2007/0129282	06-07-07	Ahlem et al			10-08-99
	2007/0077201	04-05-07	Reading et al			09-29-04
	2007/0014719	01-18-07	Reading et al			09-29-04
	2006/0088473	04-27-06	Dowding et al			10-01-04
	2006/0079492	04-13-06	Ahlem et al			10-25-99
	2006/0073099	04-06-06	Frincke et al			10-01-04
	2006/0063749	03-23-06	Ahlem et al			06-16-99
	2005/0282732	12-22-05	Ahlem et al			06-16-99
	2005/0256095	11-17-05	Ahlem et al			06-16-99
	2005/0159366	07-21-05	Ahlem et al			06-16-99
	2004/0242618	12-02-04	Lardy et al			04-01-03
	2004/0220114	11-04-04	Ahlem et al			10-08-99
	2004/0116359	06-17-04	Ahlem et al			06-16-99
	2004/0097406	05-20-04	Ahlem et al			06-16-99
	2004/0043973	03-04-04	Ahlem et al			03-16-00
	2003/0060425	03-27-03	Ahlem et al			10-08-99

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT SHEET 3 OF 4	ATTY. DOCKET NO. 302.1	APPLICATION NO. 10/814,503
	APPLICANT Henry Lardy, et al	
	FILING DATE 30-Mar-2004	GROUP 1617

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY / REGION	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 363 128	04-11-90	EPO				
	WO 87/01706	03-26-87	WO				
	WO 91/00732	01-24-91	WO				
	WO 91/00733	01-24-91	WO				
	WO 95/07926	03-23-95	WO				
	WO 95/21617	08-17-95	WO				
	WO 97/37662	10-16-97	WO				
	WO 99/63973	12-16-99	WO				

EXAMINER INITIAL	OTHER DOCUMENTS
	Chambaz, et al, Urinary steroids in neonates: Characterization of four androstenetrols by gas chromatography and mass spectrometry <i>Proceedings of Acad. Sc. Paris Series D</i> , 268:2817-2820, 1969 (translated from French).
	Chang, et al., Suppression of A δ -Androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells, <i>Proc. Natl. Acad. Sci. USA.</i> , 96(20):11173-11177, September 28, 1999
	Counsell, et al, Anabolic agents. Derivatives of 5 α -androst-1-ene <i>J. Org. Chem.</i> 27:248-253, 1962
	Hackenberg et al., Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 β ,17 β -diol in human mammary cancer cells, <i>J. Steroid Biochem. Molec. Biol.</i> , 46(5):597-603, 1993
	Henderson, Dehydroepiandrosterone and 16 α -bromo-epiandrosterone: Inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes, <i>Carcinogenesis</i> , 2(7):683-686, 1981.
	Lardy, et al., Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone, <i>Steroids</i> , 63:158-165, 1998.
	Miyamoto, et al., Δ^5 -androstenediol is a natural hormone with androgenic activity in human prostate cancer cells, <i>Proc. Natl. Acad. Sci. U. S. A.</i> 95(19):11083-11088, 1998.
	Miyamoto, et al., 3 β -Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity, <i>Proc. Natl. Acad. Sci. USA</i> , 100:4440-4444, 2003.
	Pashko, et al., Dehydroepiandrosterone (DHEA) and 3 beta-methylandrost-5-en-17-one: inhibitors of 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice, <i>Carcinogenesis</i> 5(4):463-466 1984.
	Rao, et al., Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone, <i>Cancer Res.</i> 59(13):3084-3089, 1999.
	Schubert, et al, Stereospecific hydrogenation of 4-, 1,4-, 4,6- and 1,4,6-3-ketosteroids by <i>Clostridium Paraputrificum</i> <i>Steroids Suppl</i> 1, 175-184, 1965,
	Segaloff, et al, Hormonal therapy in cancer of the breast II. Effect of methylandrostenediol on clinical course and hormonal excretion, <i>Cancer</i> , 5(2):271-74, 1952.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT SHEET 4 OF 4	ATTY. DOCKET NO. 302.1	APPLICATION NO. 10/814,503
	APPLICANT Henry Lardy, et al	
	FILING DATE 30-Mar-2004	GROUP 1617

EXAMINER INITIAL	OTHER DOCUMENTS
	Segaloff, et al, Hormonal therapy in cancer of the breast IV. Effect of androstenediol on clinical course and hormonal excretion, <i>Cancer</i> , 5(6):271-74 1952.
	Segaloff, et al, Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretion, <i>Cancer</i> , 6(3):483-487 1953.
	Segaloff, et al, Testosterone and miscellaneous steroids in the treatment of advanced mammary cancer, <i>Cancer</i> , 1957, 10(4):808-812.
	Shackleton, et al, Metabolism of fetal and neonatal adrenal steroids, <i>J. Steroid. Biochem.</i> , 1979, 11:523 – 529.
	Stillwell, et al, Characterization of metabolites of steroid contraceptives by gas chromatography and mass spectroscopy, <i>J. Steroid Biochem.</i> 3:699-706, 1972.
	Wild, et al., Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro, <i>J. Steroid. Biochem. Mo.I Biol.</i> 45:407-420, 1993,

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	